Skip Ribbon Commands
Skip to main content
Navigate Up


Listed below are brief descriptions of the CAMH diagnostics that are available for licensing. Follow the links to read a non-confidential summary of each technology. 
Feel free to contact our office should you require more information or wish inquire about the first steps in securing a licensing deal.

Diagnostics for Intellectual Disability​
Brief Description: 
Our scientists have discovered a nonsense mutation in the TRAPPC9 gene and a missense mutation in the NSUN2 gene that allows for the direct diagnosis of intellectual disability with a predictive value of nearly 100%. These markers would strengthen the genetic testing menu of a diagnostic company, and may support therapeutic interventions for intellectual disability. Click here to read more.

Brief Description:
 Our researches have developed a proprietary microarray-based technology for DNA methylation profiling in large genomes. They have identified a number of epigenetic markers associated with major psychosis; namely, schizophrenia and bipolar disorder. Epigenetic disease markers will enable us to identify individuals at risk of these diseases and enroll them in prevention programs. They will also create new opportunities for the rational design of the next generation of drugs for psychiatric disease. Click here to read more.



 Contact Us

​For more information, contact:
Dr. Klara Vichnevetski​
Director, Industry Partnerships and Technology Transfer ​
(416) 535-8501 ext. 6056 ​
CAMH Switchboard 416-535-8501
CAMH General Information Toronto: 416-595-6111 Toll Free: 1-800-463-6273
Connex Ontario Help Lines
Queen St.
1001 Queen St. W
Toronto, ON
M6J 1H4
Russell St.
33 Russell St.
Toronto, ON
M5S 2S1
College St.
250 College St.
Toronto, ON
M5T 1R8
Ten offices across Ontario